Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity

Clinical Science

Volumn 121, Issue 3, 2011, Pages 107-117

  Gault, Victor A ^a   Kerr, Barry D ^a   Harriott, Patrick ^b   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic polypeptide (GIP); Glucose lowering; Insulin secretion; Liraglutide; ob ob mice

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; LIRAGLUTIDE; N ACGIP(LYS37MYR); TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN SYNTHESIS;

ANIMALS; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, OBESE; MODELS, BIOLOGICAL; OBESITY;

EID: 79955583163     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110006     Document Type: Article

References (48)

1. Robertson, R. P., Kendall, D. M. and Seaquist, E. R. (2010) Diabetes: Strategies to prevent the type 2 diabetes mellitus epidemic. Nat. Rev. Endocrinol. 6, 128-129.
2. Currie, C. J., Peters, J. R. and Evans, M. (2010) Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008. Diabet. Med. 27, 744-752.
3. Baggio, L. L. and Drucker, D. J. (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157.
4. Creutzfeldt, W. (2001) The entero-insular axis in type 2 diabetes: incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes 109, S288-S303.
5. Flatt, P. R., Bailey, C. J. and Green, B. D. (2009) Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr. Drug Metab. 10, 125-137.
6. Lovshin, J. A. and Drucker, D. J. (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5, 262-269.
7. Deacon, C. F., Johnsen, A. H. and Holst, J. J. (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952-957.
8. Kieffer, T. J., McIntosh, C. H. and Pederson, R. A. (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585-3896.
9. Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E. and Gallwitz, B. (2004) Secretion, degradation and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53, 654-662.
10. Fonseca, V. A., Zinman, B., Nauck, M. A., Goldfine, A. B. and Plutzky, J. (2010) Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. Am. J. Med. 123, S2-S10.
11. Drab, S. R. (2010) Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 30, 609-624.
12. Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M. and Agersø, H. (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once-daily administration. J. Med. Chem. 43, 1664-1669.
13. Juhl, C. B., Hollingdal, M., Sturis, J., Jakobsen, G., Agersø, H., Veldhuis, J., Pørksen, N. and Schmitz, O. (2002) Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51, 424-429.
14. Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M. and Matthews, D. R. (2009) Efficacy and safety comparison of liraglutide, glimepride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32, 84-90.
15. Bregenholt, S., Møldrup, A., Blume, N., Karlsen, A. E., Nissen, A. E., Friedrichsen, B., Tornhave, D., Knudsen, L. B. and Petersen, J. S. (2005) The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 330, 577-584.
16. Ribel, U., Larsen, M. O., Rolin, B., Carr, R. D., Wilken, M., Sturis, J., Westergaard, L., Deacon, C. F. and Knudsen, L. B. (2002) NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur. J. Pharmacol. 451, 217-225.
17. Chang, A. M., Jakobsen, G., Sturis, J., Smith, M. J., Bloem, C. J., An, B., Galecki, A. and Halter, J. B. (2005) The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52, 1786-1791.
18. Feinglos, M. N., Saad, M. F., Pi-Sunyer, F. X., An, B. and Santiago, O (2005) Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet. Med. 22, 1016-1023.
19. Gault, V. A., Flatt, P. R., Bailey, C. J., Harriott, P., Greer, B., Mooney, M. H. and O'Harte, F. P. (2002) Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem. J. 367, 913-920.
20. O'Harte, F. P., Gault, V. A., Parker, J. C., Harriott, P., Mooney, M. H., Bailey, C. J. and Flatt, P. R. (2002) Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 45, 1281-1291.
21. Gault, V. A., Flatt, P. R., Harriott, P., Mooney, M. H., Bailey, C. J. and O'Harte, F. P. (2002) Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotropic polypeptide. J. Endocrinol. 176, 133-141.
22. Hinke, S. A., Gelling, R. W., Pederson, R. A., Manhart, S., Nian, C., Demuth, H. U. and McIntosh, C. H. (2002) Dipeptidyl peptidase IV-resistant [d-Ala2]glucosedependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 51, 652-661.
23. Irwin, N., Green, B. D., Gault, V. A., Greer, B., Harriott, P., Bailey, C. J., Flatt, P. R. and O'Harte, F. P. (2005) Degradation, insulin secretion, and antihyperglycaemic actions of two palmitate-derivatized, N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. J. Med. Chem. 48, 1244-1250.
24. Irwin, N., Gault, V. A., Green, B. D., Greer, B., Harriott, P., Bailey, C. J., Flatt, P. R. and O'Harte, F. P. (2005) Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biol. Chem. 386, 679-687.
25. Irwin, N., Green, B. D., Mooney, M. H., Greer, B., Harriott, P., Bailey, C. J., Gault, V. A., O'Harte, F. P. and Flatt, P. R. (2005) A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J. Pharmacol. Exp. Ther. 314, 1187-1194.
26. Irwin, N., O'Harte, F. P., Gault, V. A., Green, B. D., Greer, B., Harriott, P., Bailey, C. J. and Flatt, P. R. (2006) GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J. Med. Chem. 49, 1047-1054.
27. Irwin, N., Clarke, G. C., Green, B. D., Greer, B., Harriott, P., Gault, V. A., O'Harte, F. P. and Flatt, P. R. (2006) Evaluation of the antidiabetic activity of DPP-IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem. Pharmacol. 72, 719-728.
28. Lamont, B. J. and Drucker, D. J. (2008) Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 57, 190-198.
29. Kerr, B. D., Irwin, N., O'Harte, F. P., Bailey, C. J., Flatt, P. R. and Gault, V. A. (2009) Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem. Pharmacol. 78, 1008-1016.
30. Aaboe, K., Knop, F. K., Vilsboll, T., Vølund, A., Simonsen, U., Deacon, C. F., Madsbad, S., Holst, J. J. and Krarup, T. (2009) KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 4, 603-608.
31. Hojberg, P. V., Vilsboll, T., Rabol, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J. and Madsbad, S. (2009) Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52, 199-207.
32. Knudsen, L. B. (2004) Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J. Med. Chem. 47, 4128-4134.
33. Clodfelter, D. K., Pekar, A. H., Rebhun, D. M., Destrampe, K. A., Havel, H. A., Myers, S. R. and Brader, M. L. (1998) Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide. Pharm. Res. 15, 254-262.
34. Bailey, C. J., Flatt, P. R. and Atkins, T.W. (1982) Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obes. 6, 11-21.
35. Flatt, P. R. and Bailey, C. J. (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20, 573-577.
36. Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J. and Kurtzhals, P. (2004) The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. 21, 1498-1504.
37. Knudsen, L. B., Nielsen, P. F., Steensgaard, D. B., Bloch, P., Lau, J. and Agersoe, H. (2009) Liraglutide, the once-daily human GLP-1 analogue, has a protracted profile based on both delayed absorption and a long plasma half-life. Diabetologia 52 (Suppl. 1), A775.
38. Steensgaard, D. B., Thomsen, J. K., Olsen, H. B. and Knudsen, L. B. (2008) The molecular basis for the delayed absorption of the once-daily human GLP-1 analog, Liraglutide. Diabetes 57 (Suppl. 1), A164.
39. Kerr, B. D., Flatt, P. R. and Gault, V. A. (2010) Effects of γ-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1. Biochem. Pharmacol. 80, 396-401.
40. Kuhn-Wache, K., Hoffman, T., Manhart, S., Brandt,W. and Demuth, H. U. (2003) The specificity of DPP IV for natural substances is peptide structure determined. Adv. Exp. Med. Biol. 524, 57-63.
41. Woods, S. C., West, D. B., Stein, L. J., McKay, L. D., Lotter, E. C., Porte, S. G., Kenney, N. J. and Porte, Jr, D. (1981) Peptides and the control of meal size. Diabetologia 20, 305-313.
42. Kastin, A. J., Akerstrom, V. and Pan,W. (2002) Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 18, 7-14.
43. Kastin, A. J. and Akerstrom, V. (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 27, 313-318.
44. McClean, P. L., Gault, V. A., Harriott, P. and Holscher, C. (2010) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 630, 158-162.
45. Holscher, C. (2010) The role of GLP-1 in neuronal activity and neurodegeneration. Vitam. Horm. 84, 331-354.
46. Holst, J. J., Burcelin, R. and Nathanson, E. (2011) Neuroprotective properties of GLP-1: theoretical and practical applications. Curr. Med. Res. Opin. 27, 547-558.
47. Flatt, P. R. and Bailey, C. J. (1981) Development of glucose intolerance and impaired plasma insulin response to glucose in obese hyperglycaemic (ob/ob) mice. Horm. Metab. Res. 13, 556-560.
48. Holst, J. J., Vilsbøll, T. and Deacon, C. F. (2009) The incretin system and its role in type 2 diabetes mellitus. Mol. Cell. Endocrinol. 297, 127-136.